NCT06264921 - A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 23, 2024

Primary Completion Date

April 7, 2025

Study Completion Date

April 16, 2025

Conditions

Solid TumorSolid Tumor, AdultAdvanced Solid TumorMetastatic TumorOvarian CancerOvarian NeoplasmsOvarian CarcinomaMetastatic Ovarian CarcinomaEndometrial CancerEndometrial NeoplasmsEndometrial DiseasesMetastatic Endometrial CancerMetastatic Endometrial CarcinomaAdvanced Endometrial CarcinomaAdvanced Ovarian CarcinomaGastric CancerAdvanced Gastric CarcinomaMetastatic Gastric CancerMetastatic Gastric CarcinomaSmall-cell Lung CancerSmall Cell Lung CarcinomaTriple Negative Breast CancerTriple Negative Breast NeoplasmsPlatinum-resistant Ovarian CancerPlatinum-refractory Ovarian CarcinomaCCNE1 AmplificationHormone Receptor Negative Breast CarcinomaHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastProgesterone-receptor-positive Breast Cancer

Interventions

DRUG

NKT3447

Oral CDK2 inhibitor

Trial Locations (8)

30909

Augusta University Georgia Cancer Center, Augusta

34747

AdventHealth Cancer Institute, Celebration

40202

Norton Cancer Institute - Broadway, Louisville

44718

The Gabrail Pharmacology Phase 1 Research Center, Canton

78758

Texas Oncology-Austin Midtown NEXT Oncology, Austin

80218

Sarah Cannon Research Institute at HealthONE, Denver

84119

START Mountain Region, West Valley City

94158

University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco